Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Abstract Text:

Viktor Magdolen,Achim Krüger,Sumito Sato,Jutta Nagel,Stefan Sperl,Ute Reuning,Peter Rettenberger,Ulla Magdolen,Manfred Schmitt,

Tumor cell invasion and metastasis depend on the coordinated and temporal expression of proteolytic enzymes to degrade the surrounding extracellular matrix and of adhesion molecules to remodel cell-cell and/or cell-matrix attachments. The tumor cell-associated urokinase-type plasminogen activator system, consisting of the serine protease uPA, its substrate plasminogen, its membrane-bound receptor uPAR, as well as its inhibitors PAI-1 and PAI-2, plays an important role in these pericellular processes. Especially, association of the proteolytic activity of uPA with the cell surface via interaction with uPAR significantly increases the invasive capacity of tumor cells. Consequently, various approaches have been pursued to interfere with the expression or activity of uPA and/or uPAR, including antisense strategies and the development of active-site inhibitors of uPA or inhibitors of uPA/uPAR interaction. In this review, we focus on the results obtained in vitro and in vivo with tumor cells producing high levels of a recombinant soluble form of uPAR, which efficiently inhibits uPA binding to cell surface-associated uPAR and, by this, acts as a scavenger for uPA.

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Publishing Authors By Initials

V Magdolen,A Krüger,S Sato,J Nagel,S Sperl,U Reuning,P Rettenberger,U Magdolen,M Schmitt,

For similar enzymes and coenzymes: enzymes: hydrolases: peptide hydrolases: endopeptidases: serine endopeptidases: urinary plasminogen activator research abstracts see: enzymes and coenzymes: enzymes: hydrolases: peptide hydrolases: endopeptidases: serine endopeptidases: urinary plasminogen activator research

PUBMED ID PMID:

MEDLINE DATE:

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Journal Published:

PUBLICATION TYPE: Review

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 162

Page Numbers: 43-63

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 2003

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Information

Number of References: 90

LANGUAGE: eng

NlmUniqueID: 44671

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Keywords Mesh Terms:

KEYWORDS: Urinary Plasminogen Activator

MESH TERMS: metabolism

Chemical & Substance for Abstract: Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Information

Substance Name: Urinary Plasminogen Activator

Registry Number: EC 3.4.21.73

Grant and Affiliation Information for Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.

AFFILIATION: Klinische Forschergruppe der Frauenklinik der TU München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675 Munich, Germany.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo Related Publications

• ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.
• Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical practice in randomized controlled clinical trials.
• Biomechanical and immunohistochemical analysis of high hydrostatic pressure-treated Achilles tendons.
• Chapter 22: Assuring the quality, safety and efficacy of HPV vaccines: The scientific basis of regulatory expectations pre- and post-licensure.
• Concomitant use of medications with anticholinergic properties and acetylcholinesterase inhibitors: impact on cognitive and physical functioning in Alzheimer disease.
• Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression.
• Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
• Effects of carrageenan and morphine on acute inflammation and pain in Lewis and Fischer rats.
• Effects of porcine bile on survival of Bacillus cereus vegetative cells and Haemolysin BL enterotoxin production in reconstituted human small intestine media.
• Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.
• Estimating the onset of cambial activity in Scots pine in northern Finland by means of the heat-sum approach.
• Force plate for measuring the ground reaction forces in small animal locomotion.
• Forelimb and hindlimb forces in walking and galloping primates.
• FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf.
• Gynecological cytology: too old to be a pop star but too young to die.
• Hearing aid device that can be worn in the ear with a housing.
• Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner.
• Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
• Immunohistochemical expression of VEGF-A and its ligands in non-neoplastic lesions of the breast sampling-assisted by dynamic angiothermography.
• Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix.
• Methodological issues in the assessment of substance use phenotypes.
• Prediction of lung cancer using volatile biomarkers in breath.
• Protection-based assays to measure aminoacyl-tRNA binding to translation initiation factors.
• Regulatory T cells--the renaissance of the suppressor T cells.
• Requirement of subunit co-assembly and ankyrin-G for M-channel localization at the axon initial segment.
• The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo.
• The association of pregnancy and the development of obesity - results of a systematic review and meta-analysis on the natural history of postpartum weight retention.
• The binding of advanced glycation end products to cell surfaces can be measured using bead-reconstituted cellular membrane proteins.
• The evolution of asymmetric genitalia in spiders and insects.
• [Cardiac imaging in clinical electrophysiology]